Table 1 Clinical diagnostic value of CSF chemokine biomarkers for neurosyphilis.
From: CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients
Biomarker | AUC* | 95% CI# | Optimal cut-off | Sensitivity | Specificity |
|---|---|---|---|---|---|
CSF CXCL13 | 0.940 | 0.913–0.967 | 256.4 pg/ml | 85.4% | 89.1% |
CSF CXCL8 | 0.899 | 0.863–0.935 | 48.1 pg/ml | 79% | 90.1% |
CSF CXCL10 | 0.915 | 0.881–0.950 | 163.1 pg/ml | 79.6% | 91.1% |
CSF/Serum ratio of CXCL13 | 0.963 | 0.942–0.983 | 4.36 | 86.6% | 99% |
CSF/Serum ratio of CXCL8 | 0.846 | 0.799–0.892 | 10.3 | 79% | 73.3% |
CSF/Serum ratio of CXCL10 | 0.926 | 0.893–0.959 | 1.02 | 86% | 92.1% |
Model1 | 0.949 | 0.926–0.972 | 1.1 | 90.4% | 82.9% |
Model2 | 0.966 | 0.945–0.986 | 2.23 | 90.4% | 93.7% |
CSF VDRL | 0.952 | 0.925–0.980 | 1 | 90.4% | 100% |
